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A new subtype of CD4+ T lymphocytes characterized by the production of interleukin 17, i.e., TH17 cells, has been recently
described. This novel T cell subset is distinct from type 1 and type 2 T helper cells. The major feature of this subpopulation is to
generate significant amounts of pro-inflammatory cytokines, therefore appearing to be critically involved in protection against
infection caused by extracellular microorganisms, and in the pathogenesis of autoimmune diseases and allergy. The dynamic
balance among subsets of T cells is important for the modulation of several steps of the immune response. Disturbances in this
balance may cause a shift from normal immunologic physiology to the development of immune-mediated disorders. In
autoimmune diseases, the fine balance between the proportion and degree of activation of the various T lymphocyte subsets can
contribute to persistent undesirable inflammatory responses and tissue replacement by fibrosis. This review highlights the
importance of TH17 cells in this process by providing an update on the biology of these cells and focusing on their biology and
differentiation processes in the context of immune-mediated chronic inflammatory diseases.
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Introduction
Early studies by Mosmann et al. (1) have demonstrated
that CD4+ T cells could polarize into two different subsets,
T helper 1 (Th1) and T helper 2 (Th2), based on the profile
of the cytokines secreted (1). Later on, several investiga-
tors highlighted the existence of a neutral subset, Th0,
able to produce either Th1 or Th2 cytokines. It is becoming
increasingly clear that antigenic stimulation and the pecu-
liar intrinsic characteristics of the milieu induce naive T
cells to proliferate and differentiate into different effector T
cell subsets with specific features such as cytokine pro-
duction and functional properties (2).
Th1 cells are mainly characterized by the production of
large quantities of interferon-gamma (IFN-γ), while Th2
cells secrete interleukin (IL)-4, IL-5, and IL-13. Th1 cells
are the main agents in delayed type hypersensitivity im-
mune response through activation of macrophages, and
are crucial to host defense against intracellular pathogens.
In contrast, Th2 cells are more efficient in mounting hu-
moral immune responses, triggering the production of
antibodies and promoting eosinophil infiltration. Th2 re-
sponses are important to limit extracellular pathogens and
can also counterbalance Th1 immune responses. Th0
cells can differentiate into Th1 or Th2 subsets at very early
stages of cell activation. Since Th1 cells are fully capable
of secreting cytokines, they can in turn inhibit Th2 cell
differentiation and vice versa. Several regulatory mol-
ecules are involved in this process, such as cytokines,
cytokine receptors and transcription factors, ultimately lead-
ing to epigenetic modifications in the target T cells (Figure 1).
The control of immune responses is important for proper
functioning of the immune system and necessary to avoid
immunopathology, largely manifesting as allergic and au-
toimmune diseases. In human autoimmunity, the Th1 im-
mune responses have been traditionally associated with
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the induction and progression of disease. However, this
paradigm has been recently challenged following the ob-
servation in mouse models that the absence of IFN-γ
signaling does not constitute resistance to the develop-
ment of autoimmunity; on the contrary, these animals are
even more susceptible to these diseases. These observa-
tions have called the interplay of Th1 cells and autoim-
mune diseases into question, pointing to the possible
existence of additional T cell subtypes, which differ from
the Th1 subpopulation and are able to induce and perpetu-
ate local inflammation and autoimmunity.
TH17: An overview
The initial studies on TH17 cells have involved reports
on Borrelia burgdorferi infection in animal models. Stimula-
tion with sonicates and synthetic antigens of the bacteria
induced IL-17 production by T cells, independently of the
production of Th1 and Th2 cytokines. The same pattern of
IL-17 secretion was induced by the BCG strain of Myco-
bacterium bovis (3). Further evidence that led to the dis-
covery of this cell population came from studies in autoim-
mune murine models, namely rheumatoid arthritis (RA)
and multiple sclerosis models (MS) (4,5). The cumulative
evidence about the existence of a distinct subset of T cells
characterized by the secretion of large amounts of IL-17
has led to the proposal of a third lineage of Th cells
designated TH17 cells (6,7).
IL-17 (also known as IL17A) and IL-17F cytokines are
members of the IL17 family, which encompasses potent
inducers of inflammation, promoting cellular infiltration and
the production of several pro-inflammatory cytokines and
chemokines. IL-17 binds to and signals through IL17 re-
ceptor A (IL-17RA), a member of the IL17R family that is
Figure 1. Schematic representation of naive CD4 T cells under different stimuli and possible differentiation pathways. IFN-γ =
interferon gamma: IL = interleukin; TGF-β = transforming growth factor beta; Th1, Th2 = T helper cells 1 and 2; TREG = regulatory T
cells; M-CSF and GM-CSF = macrophage and granulocyte-macrophage colony-stimulating factor; LB = B lymphocytes.
IFN-γ, IL-2 IL-4, IL-5, IL-13 IL-17, IL-22, IL-26,
M-CSF, GM-CSF
IL-10, TGF-β
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largely expressed by epithelial cells and mesenchymal
cells such as endothelial cells and fibroblasts. The genes
that encode IL-17 and IL-17F are located on the same
chromosome in both mice and humans. The majority of
studies on the subject have focused on IL-17 or IL-17A. It
is known that IL-17F has pro-inflammatory characteristics
similar to those of IL-17, albeit with weaker activity than the
homologous IL-17A. Some studies in humans have pro-
posed a possible function of IL-17F in the physiopathology
of human asthma. The present review will focus mainly on
IL-17 since it is the major cytokine produced by TH17 cells,
but the IL-17 family members also comprise IL-17B, IL-
17C, IL-17D, and IL-17E (also known as IL-25) secreted by
a large number of cells (8).
With the discovery of TH17 cells, many questions
about the physiopathology of certain chronic inflammatory
diseases can now be better understood, since the mech-
anism of such immune responses did not fit under the Th1
or Th2 paradigm. The neutralization of IL-17, without inter-
fering with the Th1 effective pathway, is capable of offering
full recovery from some murine autoimmune diseases,
such as collagen-induced arthritis (CIA) and experimental
autoimmune encephalitis (EAE) (5,9). The effectiveness of
such an approach could be achieved when the treatment is
administered during priming or even when the disease is
already established (5,9). Recently, other studies have
associated the participation of TH17 cells in the patho-
physiology of several human inflammatory diseases, in-
cluding viral hepatitis (10), asthma (11,12) and transplant
rejection (13).
The discovery of IL-23 shed light on the differentiation
route of this novel T cell phenotype. This cytokine is a
dimer composed of the subunits IL-12p40 and IL-23p19.
While the IL-12p40 subunit is a common chain for IL-12
and IL-23, the IL-23p19 and IL-12p35 subunits are exclu-
sive of IL-23 and IL-12, respectively. Mild autoimmune
manifestations have been observed in mice susceptible to
autoimmunity when knocked out for IL-12p40. In contrast,
in IL-12p35 receptor knockout animals, the development
of autoimmunity occurred normally. Taken together, these
studies indicate that IL-23, but not IL-12, is a crucial ele-
ment in promoting autoimmunity. The human counterpart
of these findings comes from the observation that anti-
bodies against the IL-12p40 subunit were effective in the
treatment of Crohn’s disease (14) and showed good re-
sults in clinical trials with patients with MS and psoriasis
(15,16).
Although IL-23 is fundamental for survival and for ter-
minal differentiation of TH17 cells, its exact function in the
induction of these cells has yet to be fully understood. This
is partly due to the absence of the IL-23 receptor in the
naive T cells, and its expression only in activated cells.
Thus, only previously activated or memory T cells become
susceptible to the action of IL-23 and as such, amenable to
differentiate into TH17 cells (17). Different alternative fac-
tors of differentiation for TH17 cells have been identified.
Three independent studies directly addressed this issue
by reporting TGF-β and IL-6 as the main cytokines able to
induce the differentiation of naive T cells into TH17 lym-
phocytes (18-20). Sutton et al. (21) also reported on the
importance of IL-1 and IL-23 as differentiation factors and
as survival promoters in murine studies. Evans et al. (22)
reported that the induction of TH17 cells is mediated by
cell-cell contact with Toll-like receptor-activated mono-
cytes in the context of T cell receptor ligation.
A recent study has added further complexity to the
understanding of the TH17 induction pathway and its func-
tion. In a mouse model, McGeachy et al. (23) showed that
TH17 cells produce IL-17 in the presence of IL-6 and TGF-
β, but they do not have pathogenic potential in vivo, even
with a high production of IL-17. Apparently, this in vivo
behavior was due to their capacity to also produce IL-10
that has modulatory effects on the action of IL-17. How-
ever, TH17 cells stimulated in the presence of IL-23 also
promoted the expression of pro-inflammatory IL-17 and
chemokines, but did not produce IL-10. Thus, it seems that
IL-6 and TGF-β initiate the polarization towards TH17
cells, but these cells would be devoid of pathogenic poten-
tial in vivo unless there was the participation of IL-23
capable of providing immune inflammatory capacity to
TH17 cells (23).
Several other cytokines may interfere with the develop-
ment and proliferation of TH17 cells. The neutralization of
Th1 and Th2 cytokines, such as IFN-γ and IL-4, increases
the number of IL-17-producing cells generated by stimula-
tion with IL-23 (24). More recently, it was demonstrated
that IL-27, IL-25, and IL-13 have inhibitory functions on
TH17 development. The absence of these cytokines exac-
erbates inflammatory processes and increases the num-
ber of TH17 cells in an inflammatory milieu (9,25). Akin to
what has been previously observed for Th1 and Th2 cell
polarization, the presence of co-stimulatory molecules such
as CD80, CD86, OX40, and ICOS is fundamental for TH17
differentiation in the presence of IL-23 (24).
As mentioned earlier, TH17 cells have an important
function in protecting against infection by extracellular
microorganisms due to their ability to secrete pro-inflam-
matory effector cytokines such as IL-21, IL-22, and IL-26,
as well as smaller quantities of IL-6 and TNF-α (Figure 2).
The continuous balance among T cell subsets during
the course of pathology is of primordial importance to
define the outcome of the disease. Specific transcription
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factors regulate the commitment and the stability of these
T cell subsets. T-bet is involved in the polarization of Th1-
specific T cells, while GATA-3 is related to Th2 differentia-
tion, and the transcription factor Foxp3 is important for
regulatory T cell commitment. Recently, two transcription
factor members of the retinoic acid receptor-related or-
phan (ROR) nuclear hormone receptor family were shown
to regulate the differentiation of TH17 cells. The first to be
described was RORy, which is encoded by the RORC
gene and is best represented by the isoform RORyt, which
is exclusively expressed in cells of the immune system.
This transcription factor is induced by TGF-β and IL-6, and
the overexpression of RORyt polarizes Th0 cells into the
TH17 lineage and blocks the Th1 and Th2 pathways. The
knockout of RORyt in Th0 cells inhibits IL-17 and IL-17F
expression in response to TGF-β and IL-6 or IL-21, and
restrains TH17 differentiation. Recently, it was reported
that RORα was also expressed by TH17 cells and induced
by TGF-β and IL-6. This transcription factor has properties
similar to those of its homologue and could inhibit Th1 and
Th2 differentiation. Interestingly, RORα deficiency in T
cells results in a selective decrease in IL-17 and IL-23R
expression, but has only a mild inhibitory effect on EAE
induction, while the deficiency of its counterpart (RORyt)
results in attenuated autoimmune development in the EAE
model (26). In summary, RORyt and RORα have a syner-
gistic effect on TH17 differentiation, while in vivo they are
induced at the same time in an inflammatory milieu, but
with some differences in regulating biological functions of
TH17 cells depending on the disease model.
TH17 cells in animal models of autoimmune
diseases
Although the first evidence of IL-17-producing cells
came from studies of a murine model of infectious dis-
eases, the greatest advances in understanding the im-
mune functions of these cells were based on data on
murine models of autoimmunity. IL-17 is directly involved
in the pathophysiology of experimental arthritis. In the
absence of IL-17, these mouse models developed mild
articular disease (4). In the CIA model, rats treated with an
antagonist of the IL-17 receptor (IL-17R) had significantly
reduced manifestations (27). Treatment with anti-IL-17
monoclonal antibodies led to an improvement in articular
destruction in mice with CIA (28). In EAE, the deficiency of
IL-17 or the use of IL-17-blocking antibodies prevented the
development of the disease or diminished its severity (5).
Figure 2. TH17 lymphocytes are critically involved in activating and maintaining the inflammatory response against microorganisms
on the basis of their capacity to produce inflammatory mediators and characteristic migration to inflamed sites. The figure represents
some cells susceptible to the action of IL-17 and IL-22 with their respective effects on target cells. TCR = T cell antigen receptor; ROR
= retinoic acid receptor-related orphan; IL = interleukin; CCR = chemokine (C-C motif) receptor; MHC = major histocompatibility
complex; MCP-1 = monocyte chemotactic protein-1.
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In the last 3 years, many studies have demonstrated
the importance of TH17 cells in the pathogenesis of auto-
immune inflammatory diseases, basically showing its path-
ogenic function. In a more recent study, it was shown that
IL-17 also contributes to the formation of lymph node
germinative centers and to the production of autoantibod-
ies in mice with lupus-like disease (29). In murine models
of colitis, significant reduction in the migration of neutro-
phils to the colon and reduced amounts of CXC chemo-
kines were achieved in IL-17R knockout mice, or by block-
ing IL-17R using IL-17R-Ig fusion protein, thereby demon-
strating the critical role of IL-17 and IL-17R signaling in gut
inflammation (30). The blockage of IL-23 was effective in
preventing colitis by inhibiting IL-17 and IL-6 production in
IL-10-deficient mice (31). Finally, another study of a colitis
model showed that IL-23 acts as an effector cytokine within
the innate intestinal immune system by inducing intestinal
inflammation in response to activation through CD40. The
treatment with anti-IL-23 was able to prevent IL-17 produc-
tion and development of colitis independently of the action
of T cells, since the disease was reproduced in T cell-
deficient mice. All of these data suggested the possible
contribution of other cells, such as non-conventional lym-
phocytes, as a source of IL-17 (11).
Distinctive characteristics of human TH17
cells
The current concepts on the differentiation of TH17
cells have been drawn from murine models. Given the
importance of the cytokine members of the IL-17 family in
the pathogenesis of some human diseases, it is of funda-
mental importance to understand how this family is ex-
pressed in human T cells, especially in conditions that
could make a human naive T cell differentiate into a TH17
cell subset. The initial studies evaluating the induction of
IL-17 production by human lymphocytes showed that this
differentiation pathway is dependent on activation signal-
ing through the T cell antigen receptor in the presence of
appropriate co-stimulation, associated with the presence
of IL-23 (32). However, these studies have not taken into
consideration the stage of maturation of these cells, i.e.,
whether they were naive or memory cells.
An interesting aspect of human T helper cells is their
great plasticity for differentiation compared with their mu-
rine counterparts. IL-17-producing T cells are promptly
identified in populations of memory CD4+ T lymphocytes in
humans although their commitment to the TH17 specific
lineage is less clear since in humans these cells produce
both IL-17 and IFN-γ. In addition, unlike the TH17 murine
cells that are easily induced by the combination of TGF-β
and IL-6 cytokines, this combination is completely ineffi-
cient in generating human TH17 cells. On the other hand,
some studies in humans have shown that IL-23, in the
presence of IL-1, is effective in promoting the production of
IL-17 by T lymphocytes (33), probably by the concomitant
action of TGF-β present in the bovine fetal serum of the
medium used in the experiments.
Two recent studies evaluating naive T cells from hu-
man umbilical cord showed that the presence of TGF-β is
essential to induce the RORyt transcription factor, and in
the presence of IL-23 and IL-1, combined with inflamma-
tory cytokines such as IL-6, IL-21 and TNF-α, they ac-
quired the capacity to produce IL-17 at optimal levels.
These cells could also produce several other inflammatory
cytokines such as IL-21, IL-22, IL-6, TNF-α, and IFN-γ. The
cytokine profile produced by human TH17 cells seems to
be also influenced by other mediators present in the cul-
ture (34-36).
There are several studies of human diseases suggest-
ing an important role for IL-17 in the pathogenesis of
human inflammatory and autoimmune diseases. IL-17 is
involved in the inflammatory response observed in exacer-
bation episodes of IgA nephropathy by stimulating the
release of pro-inflammatory cytokines from peripheral blood
monocytes (37). In human renal biopsy samples, scattered
IL-17 antigen was found in borderline acute renal rejection
and could be used as a predictive parameter for subclinical
renal allograft rejection in the future (13).
TH17 has been implicated in host defense against a
number of microorganisms. IL-17 promotes expansion
and recruitment of innate immune cells such as neutro-
phils, and also cooperates with TLR ligands, IL-1β, and
TNF-α to enhance inflammatory reactions. It also stimu-
lates the production of β-defensins and other antimicrobial
peptides. Its receptor, IL-17RA, is ubiquitously expressed
and shares many features with classical innate immune
receptors. Their intracellular tail motif signaling converges
to a common inflammatory transcription pathway (38).
Full comprehension of the mechanisms of polarization
of T helper lymphocytes in humans is essential to gain a
better understanding of the physiopathological mechan-
isms of diseases and for the development of future ap-
proaches to their treatment.
TH17 cells in human autoimmune diseases
Some of the TH17 cell products are found at higher
levels in affected tissues in human diseases and in their
respective animal models (Table 1). The essential function
of this T cell subset in the induction and development of
murine autoimmune diseases has been confirmed and its
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actual role in human autoimmune diseases is now sup-
ported by a body of favorable evidence.
Studies on the participation of TH17 cells in RA have
redirected the focus of attention, hitherto limited only to
Th1 cells. The products of TH17 cells, such as IL-17 and
IL-23, are present in the serum, synovial fluid and synovial
tissue of the majority of patients with RA, while they are
absent in osteoarthritis (39-41). Under normal conditions,
IL-17 is undetectable or detected at very low levels in the
serum of healthy controls. However, high levels of this
cytokine were detected in serum and synovial fluid in two
studies evaluating patients with RA (40,42). IL-17-produc-
ing clones were recoverable from effector T cells of syn-
ovial tissue of patients with RA (43).
Peripheral blood T cells from patients with RA, co-incu-
bated with synovial fibroblasts in the presence of type II
collagen, induced the production of IL-15, TNF-α, and IL-18
by the synovial cells. In turn, T cells produced high levels of
IL-17 and IFN-γ in response to these cytokines (40).
IL-17 also stimulates an increased production of IL-6,
promotes cartilage destruction, inhibits the synthesis of
collagen, and induces bone re-absorption in patients with
RA (44,45). Synovial fibroblasts from RA patients treated
in vitro with IL-17 produce IL-6 and IL-8 and increase gene
expression for chemokines and metalloproteinases. These
cells participate in the perpetuation of joint inflammation as
dynamic partners in a mutual activation feedback via se-
cretion of cytokines and chemokines that stimulate each
other (24). Patients in the initial stages of inflammatory
arthritis progressing to the development of RA have a
distinct transitional profile of cytokines characterized by
the production of IL-2, IL-4, IL-13, IL-17, and IL-15 in
synovial fluid. Interestingly, this Th2/TH17 cytokine profile
can no longer be observed at later stages of the disease
(46). A recent 2-year prospective study also reported the
same behavior of cytokine profile at the beginning of the
disease (47). These studies support the idea that T cells
play a distinct role in the early stages of the disease,
emphasizing the action of IL-17 and other cytokines not
directly linked to TH17 cells. This initial response differs
from that occurring in late stages of disease, which are
characterized by a predominantly Th1-driven inflamma-
tory response. It is worth emphasizing that in the cited
study the authors described a positive correlation of mRNA
levels of the cytokines produced by TH17 cells, such as IL-
1, TNF-α and IL-17, with progression of articular damage.
Other studies on different autoimmune diseases such
as systemic lupus erythematosus (48), psoriasis (36,49,50),
multiple sclerosis (51,52), systemic sclerosis (53), bowel
inflammatory disease (54), ankylosing spondylitis (55),
and juvenile idiopathic arthritis (56) have demonstrated
the presence of high levels of IL-17 and other cytokines
related to its pathway in serum and tissues.
Patients with bowel inflammatory disease have high
expression of IL-17 mRNA and protein at the intracellular
level in intestinal mucosa compared to normal controls or
patients with infectious or ischemic disease (54). Annunziato
et al. (17) demonstrated the presence of CCR6+ IL-23R+
IL-17-producing cells and/or polyfunctional IL-17/IFN-γ pro-
ducing cells in the intestine of patients with Crohn’s dis-
ease. In the same study, higher serum levels of IL-17
correlated with disease exacerbation (17).
Table 1. Role of TH17 in human diseases and mouse models.
Disease TH17 related cytokines References
IL-17 IL-21 IL-22 Mouse Human
Rheumatoid arthritis Pathogenic Pathogenic ND 4,27,28 43,39-45
Multiple sclerosis Pathogenic Pathogenic ND 5,33 51,52
Systemic lupus erythematosus Pathogenic? Pathogenic ND 29 48
Systemic sclerosis Pathogenic ND Pathogenic 24 53
Inflammatory bowel disease Protective (acute) ND ND 11,30,31 54
Pathogenic (chronic)
Ankylosing spondylitis Pathogenic? ND ND None 55
Hepatitis None ND Protective 10 None
Asthma Protective (effector) Protective ND 11,12 8
Pathogenic (priming)
Contact hypersensitivity Pathogenic ND ND None 59
Psoriasis Pathogenic ND Pathogenic None 36,50,55
Kidney transplant Pathogenic ND ND 13 13
ND = not determined.
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High levels of IL-17 were detected in the skin of pa-
tients with psoriasis and this cytokine was able to induce
the expression of adhesion molecules and pro-inflamma-
tory cytokines in human keratinocytes (49). Liang et al.
(50) showed that IL-22 was also found at high levels in the
skin of patients with psoriasis and contributed, in synergy
with IL-17, to the induction of proteins associated with the
cellular processes of differentiation and proliferation in this
disease (50). In another study, Wilson et al. (36) demon-
strated that some cells from the skin of patients with
psoriasis expressed IL-23R, IL-17A, IL-17F, IL-26, CCL20,
and the RORyt transcription factor, suggesting the pres-
ence of TH17 in the skin of these patients. This study also
showed that IL-1 and IL-23 are important for the differenti-
ation of these cells (36).
In a recent study, Kebir et al. (51) reported on the
expression of receptors for IL-17 and IL-22 at the blood-
brain barrier level of MS lesions and demonstrated that IL-
17 and IL-22 contributed in vitro to the changes in the
blood-brain barrier architecture. In addition, in vitro studies
with human cells showed that TH17 lymphocytes can
efficiently cross this barrier and kill neurons by the release
of granzyme B, promoting inflammation of the central
nervous system and infiltration of further inflammatory
cells (51). Tzartos et al. (52) found high levels of IL-17
mRNA (in situ hybridization) and protein (immunohisto-
chemistry) in lymphocytes, astrocytes, and oligodendro-
cytes located in areas of active injury to the central nervous
system in patients with MS. They also observed a higher
frequency of CD4+IL-17+ and CD8+IL-17+ T lymphocytes in
areas of active lesion (73%) compared to inactive lesions
(17%) of the brain. These observations suggest that both
CD4+ cells and CD8+ IL-17-producing T cells play an
important role in MS pathophysiology (52). Figure 3 de-
picts a schematic view of the possible participation of TH17
cells in the pathophysiology of MS.
Many of the molecules currently being focused on for
therapeutic targeting in the treatment of autoimmune dis-
eases are directly or indirectly associated with the TH17
axis. Particularly noteworthy are IL-17 and GM-CSF, soluble
mediators of inflammation targeted in clinical studies and
even for immunobiological use in clinical practice such as
TNF-α, IL-6 and IL-1 blockers that could be a product or an
inducer factor for TH17 subset development. Phase I clinical
studies with antibodies against the IL-12p40 subunit (a
common chain of the IL-12 and IL-23 receptor) in patients
with psoriasis and MS have shown good “tolerance” and
positive response, yielding improvements in clinical and
laboratory parameters (15,16). A multicenter phase II study
with an anti-IL-17 monoclonal antibody (AIN45-7) is cur-
rently underway in patients with Crohn’s disease and psoria-
sis resistant to conventional therapies. These trials will help
to better understand the relevance of TH17 cells in the
pathogenesis of these diseases and to evaluate whether
anti-IL-17 therapy will result in greater efficiency and safety
benefits over conventional treatment strategies.
Final considerations
High levels of IL-17 and other inflammatory mediators
of the TH17 pathway have been observed in several
human autoimmune disorders and in related animal mod-
els. However, these results must be interpreted with cau-
tion. It is important to identify the cellular source of IL-17
and related cytokines in humans. Despite the focus on IL-
17-producing CD4+ T cells, other lymphocyte subsets might
have similar capacity, such as NKT cells, γδ T lymphocytes
and CD8+ T lymphocytes, all with the capacity to produce
IL-17 under certain circumstances (57-59).
Although the necessary conditions for induction of naive
T cells producing IL-17 may seem clear, the memory T cells
are the major source of this cytokine in humans. For this
latter T cell population, the presence of IL-23 is not neces-
sary for induction of IL-17 since a regular T cell antigen
receptor stimulus and appropriate activation of co-stimulat-
ing molecules seem to suffice. In contrast to observations in
mice, human TH17 cells also produce IFN-γ, and are thus
considered to be “double positive”. Perhaps because of the
novelty of this new subset of T lymphocytes, no specific
phenotypic surface marker for TH17 has yet been identified.
At this time, the expression of the receptor for IL-23 and the
chemokine receptor CCR6 has been used to purify IL-17+-
IFN-γ+ T cells (34,36). Despite the advances made to date by
studies in murine TH17 cells, human CD4+ T cells seem to
behave with a much greater plasticity and are thus less
“terminally differentiated”.
Further research on the basic biology of human TH17
cells is necessary, including aspects of epigenetic regula-
tion of the locus for IL-17 cytokines and other inflammatory
mediators of this lymphocyte subset. Recently, it has been
shown that human CD4posCD25highCD27posCD45RAneg
Foxp3pos regulatory T cells also possess an effector differ-
entiation program resulting in IL-17 production (60).
The TH17 element adds complexity to the traditional
concepts of immune regulation, but at the same time helps
in the understanding of issues related to immune response
such as cell differentiation, inflammatory response and its
soluble mediators as well as specific prevailing gene pat-
terns in each one of them. The ordination of cellular sub-
sets into categories and families facilitates the under-
standing of inflammatory processes in different diseases
and/or at different stages of chronic diseases.
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Figure 3. Schematic view of the participation of TH17 cells in the exacerbation of the inflammatory response in multiple sclerosis,
mediated by the increase of the cells in nervous system tissue and release of inflammatory mediators in the brain. Action of cytokines
released by TH17 on endothelial cells resulting in increased vascular permeability and production of chemokines (MCP-1, IL-8) and
inflammatory cytokines such as IL-6. Participation of TH17 cells on the destruction of neurons is mediated by the release of granzyme
B and activation of macrophages that start the production of cytokines such as granulocyte-macrophage colony-stimulating factor
(GM-CSF). IL = interleukin; MCP-1 = monocyte chemotactic protein-1.
1. TH17 cell migration from within
capillaries to the nervous tissue.
Release of cytokines such as IL-17
and IL-22 that act on these recep-
tors at the surface of endothelial
cells.
2. Vascular changes and activation
of the endothelium from the pro-
duction of chemokines (MCP-1,
IL-8) and IL-6. Chemoattraction of
cells with consequent migration to
the nervous tissue. Overflow of
plasma with soluble mediators.
3. Destruction of neurons by TH17
cells mediated by cytotoxicity de-
pendent on granzyme B (GR-B).
IL-22R / IL-17R
IL-22R
IL-17R
GR-B
GM-CSF
Macrophages
Soluble
mediators
TH17
CAPILLAR
CENTRAL NERVOUS SYSTEM
Neuron
MCP-1
IL-6
IL-8
TH17
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The understanding of IL-17 regulatory pathways is nec-
essary for a better comprehension of the pathophysiology of
autoimmune diseases and shall contribute to the develop-
ment of new opportunities for therapeutic intervention.
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